Resverlogix Corp (RFS.SG)
Chart Events
Performance Outlook
| Previous Close | 0.1540 |
| Open | 0.1580 |
| Bid | 0.1290 x N/A |
| Ask | 0.1370 x N/A |
| Day's Range | 0.1290 - 0.1580 |
| 52 Week Range | 0.0540 - 0.5050 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RFS.SG
Related Research
- Simply Wall St.
Insiders who bought in the last 12 months lose an additional US$43k as Resverlogix Corp. (TSE:RVX) drops to CA$44m
Insiders who bought US$125k worth of Resverlogix Corp.'s ( TSE:RVX ) stock at an average buy price of US$0.25 over the...
- GlobeNewswire
InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions
VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions. The company’s new focus on patients with Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflects the compelling opportunity for apabet
- GlobeNewswire
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflecting the compelling opportunity for apabetalone to benefit PCC patients and guidance from the US Food and Drug Administration (FDA). A rece
